T1	PROC 46 60	ENSAYO CLÍNICO
#1	AnnotatorNotes T1	C0008976; Clinical Trials; Research Activity
T2	CHEM 106 126	EMULSIONES LIPÍDICAS
#2	AnnotatorNotes T2	C3883356; Lipid Emulsion; Pharmacologic Substance
T3	CHEM 130 147	ACEITE DE PESCADO
#3	AnnotatorNotes T3	C0016157; fish oils; Organic Chemical · Pharmacologic Substance
T4	PROC 169 183	HOSPITALIZADOS
#4	AnnotatorNotes T4	C0019993; Hospitalization; Health Care Activity
T5	PROC 197 223	NUTRICIÓN PARENTERAL TOTAL
#5	AnnotatorNotes T5	C0030548; Parenteral Nutrition, Total; Therapeutic or Preventive Procedure
T6	ANAT 254 260	SANGRE
#6	AnnotatorNotes T6	C0005767; Blood; Body Substance
T7	PROC 283 330	ENSAYO CLÍNICO PILOTO, RANDOMIZADO, DOBLE CIEGO
T8	CHEM 377 397	EMULSIONES LIPÍDICAS
#7	AnnotatorNotes T8	C3883356; Lipid Emulsion; Pharmacologic Substance
T9	CHEM 413 430	ACEITE DE PESCADO
#8	AnnotatorNotes T9	C0016157; fish oils; Organic Chemical · Pharmacologic Substance
T10	PROC 452 466	HOSPITALIZADOS
#9	AnnotatorNotes T10	C0019993; Hospitalization; Health Care Activity
T11	PROC 480 506	NUTRICIÓN PARENTERAL TOTAL
#10	AnnotatorNotes T11	C0030548; Parenteral Nutrition, Total; Therapeutic or Preventive Procedure
T12	DISO 511 531	HIPERTRIGLICERIDEMIA
#11	AnnotatorNotes T12	C0020557; Hypertriglyceridemia; Disease or Syndrome
T13	ANAT 592 598	plasma
#12	AnnotatorNotes T13	C0032105; Plasma; Body Substance
T14	DISO 606 618	complicación
#13	AnnotatorNotes T14	C0009566; Complication; Pathologic Function
T15	DISO 558 598	elevación de los trigliceridos en plasma
T16	PROC 674 694	nutrición parenteral
#14	AnnotatorNotes T16	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T17	DISO 725 745	hipertrigliceridemia
#15	AnnotatorNotes T17	C0020557; Hypertriglyceridemia; Disease or Syndrome
T18	DISO 753 776	complicación metabólica
T19	CHEM 819 839	emulsiones lipídicas
#16	AnnotatorNotes T19	C3883356; Lipid Emulsion; Pharmacologic Substance
T20	PROC 337 369	COMPARAR LA EFICACIA Y SEGURIDAD
T21	PROC 846 872	nutrición parenteral total
#17	AnnotatorNotes T21	C0030548; Parenteral Nutrition, Total; Therapeutic or Preventive Procedure
T22	CHEM 1235 1248	triglicéridos
#18	AnnotatorNotes T22	C0041004; Triglycerides; Biologically Active Substance · Organic Chemical
T23	PROC 1319 1321	NP
#19	AnnotatorNotes T23	C0030547; Parenteral Nutrition; Therapeutic or Preventive Procedure | C0204706; Parenteral alimentation procedure; Therapeutic or Preventive Procedure | C1527385; Parenteral Feeding; Therapeutic or Preventive Procedure
T24	DISO 1396 1423	hipersensibilidad de tipo I
#20	AnnotatorNotes T24	C0020523; Immediate hypersensitivity; Pathologic Function | C0429892; Type 1 hypersensitivity response; Pathologic Function
T25	PROC 1052 1088	consentimiento informado por escrito
#21	AnnotatorNotes T25	C0811741; Obtain informed written consent; Health Care Activity
T26	CHEM 1484 1504	emulsiones lipídicas
#22	AnnotatorNotes T26	C3883356; Lipid Emulsion; Pharmacologic Substance
T27	CHEM 1580 1588	propofol
#23	AnnotatorNotes T27	C0033487; propofol; Organic Chemical · Pharmacologic Substance
T28	DISO 228 260	TRIGLICERIDOS ELEVADOS EN SANGRE
T29	PROC 643 657	administración
#24	AnnotatorNotes T29	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T30	CHEM 661 667	grasas
#25	AnnotatorNotes T30	C0015677; Fatty acid glycerol esters; Organic Chemical · Pharmacologic Substance
T31	PROC 801 815	administración
#26	AnnotatorNotes T31	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T32	PROC 1224 1248	niveles de triglicéridos
T33	PROC 184 192	TRATADOS
#27	AnnotatorNotes T33	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T34	DISO 1430 1456	reacciones idiosincrásicas
#28	AnnotatorNotes T34	C0745213; idiosyncratic reaction; Finding
T35	PROC 66 98	COMPARAR LA EFICACIA Y SEGURIDAD
T36	CHEM 228 241	TRIGLICERIDOS
#29	AnnotatorNotes T36	C0041004; Triglycerides; Biologically Active Substance · Organic Chemical
T37	CHEM 575 588	trigliceridos
#30	AnnotatorNotes T37	C0041004; Triglycerides; Biologically Active Substance · Organic Chemical
T38	PROC 467 475	TRATADOS
#31	AnnotatorNotes T38	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T39	PROC 1283 1291	tratados
#32	AnnotatorNotes T39	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T40	PROC 1567 1575	tratados
#33	AnnotatorNotes T40	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T41	Date 13 17	2018
T42	Form 106 116	EMULSIONES
T44	LIVB 151 168	PACIENTES ADULTOS
#34	AnnotatorNotes T44	C0030705; Patients; Patient or Disabled Group + C0001675; Adult; Age Group
T45	Route 207 217	PARENTERAL
#35	AnnotatorNotes T45	C1518896; Parenteral Route of Drug Administration; Functional Concept
T46	Form 377 387	EMULSIONES
T47	Route 398 409	ENDOVENOSAS
T48	LIVB 434 451	PACIENTES ADULTOS
#36	AnnotatorNotes T48	C0030705; Patients; Patient or Disabled Group + C0001675; Adult; Age Group
T50	Route 490 500	PARENTERAL
#37	AnnotatorNotes T50	C1518896; Parenteral Route of Drug Administration; Functional Concept
T51	Route 684 694	parenteral
#38	AnnotatorNotes T51	C1518896; Parenteral Route of Drug Administration; Functional Concept
T52	Form 819 829	emulsiones
T53	Route 856 866	parenteral
#39	AnnotatorNotes T53	C1518896; Parenteral Route of Drug Administration; Functional Concept
T54	LIVB 908 915	sujetos
#40	AnnotatorNotes T54	C0681850; Study Subject; Group
T55	Age 930 943	18 años o más
T57	LIVB 1006 1013	sujetos
#41	AnnotatorNotes T57	C0681850; Study Subject; Group
T58	LIVB 1169 1188	representante legal
#42	AnnotatorNotes T58	C4288823; Legal Representative for the Study; Human
T59	LIVB 1197 1204	sujetos
#43	AnnotatorNotes T59	C0681850; Study Subject; Group
T61	Duration 1300 1314	al menos 1 día
T62	LIVB 1356 1363	sujetos
#44	AnnotatorNotes T62	C0681850; Study Subject; Group
T63	Neg_cue 1364 1366	no
T64	Neg_cue 1424 1426	ni
T65	Neg_cue 1459 1465	ningún
T66	Form 1484 1494	emulsiones
T67	LIVB 1509 1554	Mujeres embarazadas o en período de lactancia
#45	AnnotatorNotes T67	C0033011; Pregnant Women; Population Group | C4316174; Patients who are breastfeeding; Patient or Disabled Group
T68	LIVB 1559 1566	Sujetos
#46	AnnotatorNotes T68	C0681850; Study Subject; Group
T69	PHYS 197 206	NUTRICIÓN
#47	AnnotatorNotes T69	C1442959; Nutrition function; Organism Function
T70	PHYS 480 489	NUTRICIÓN
#48	AnnotatorNotes T70	C1442959; Nutrition function; Organism Function
T71	PHYS 674 683	nutrición
#49	AnnotatorNotes T71	C1442959; Nutrition function; Organism Function
T72	PHYS 766 776	metabólica
#50	AnnotatorNotes T72	C0025519; Metabolism; Organism Function
T73	PHYS 846 855	nutrición
#51	AnnotatorNotes T73	C1442959; Nutrition function; Organism Function
T43	PHYS 1545 1554	lactancia
#52	AnnotatorNotes T43	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T49	PHYS 1517 1528	embarazadas
#53	AnnotatorNotes T49	C0032961; Pregnancy; Organism Function
T56	LIVB 960 971	ambos sexos
#54	AnnotatorNotes T56	C0025266; Male population group; Population Group + C0043210; Woman; Population Group
A1	Population_data T44 Age
A2	Population_data T48 Age
A3	Assertion T24 Negated
A4	Assertion T34 Negated
A5	Assertion T26 Negated
A6	Status T24 History_of
A7	Status T34 History_of
#55	AnnotatorNotes T35	C0511730; Identify product efficacy and safety issues; Health Care Activity
#56	AnnotatorNotes T20	C0511730; Identify product efficacy and safety issues; Health Care Activity
#57	AnnotatorNotes T7	C0031928; Pilot Projects; Research Activity + C0034656; Randomization; Research Activity + C0013072; Double-Blind Method; Research Activity
R1	Has_Drug_Form Arg1:T2 Arg2:T42	
R2	Combined_with Arg1:T2 Arg2:T3	
R3	Experiences Arg1:T44 Arg2:T2	
R4	Experiences Arg1:T44 Arg2:T4	
R5	Experiences Arg1:T44 Arg2:T33	
R7	Has_Route_or_Mode Arg1:T5 Arg2:T45	
R9	Experiences Arg1:T44 Arg2:T5	
R10	Experiences Arg1:T44 Arg2:T69	
R11	Experiences Arg1:T44 Arg2:T28	
R12	Location_of Arg1:T6 Arg2:T28	
#58	AnnotatorNotes T28	C0020557; Hypertriglyceridemia; Disease or Syndrome | C0853692; Blood triglycerides increased; Finding
R14	Has_Drug_Form Arg1:T8 Arg2:T46	
R15	Has_Route_or_Mode Arg1:T8 Arg2:T47	
R16	Combined_with Arg1:T8 Arg2:T9	
R17	Experiences Arg1:T48 Arg2:T8	
R18	Experiences Arg1:T48 Arg2:T10	
R19	Experiences Arg1:T48 Arg2:T38	
R20	Experiences Arg1:T48 Arg2:T11	
R21	Overlap Arg1:T4 Arg2:T5	
R23	Overlap Arg1:T4 Arg2:T33	
R26	Overlap Arg1:T10 Arg2:T38	
R28	Overlap Arg1:T10 Arg2:T11	
R30	Has_Route_or_Mode Arg1:T11 Arg2:T50	
R32	Experiences Arg1:T48 Arg2:T12	
#59	AnnotatorNotes T15	C0858041; Plasma triglycerides increased; Finding 
R33	Location_of Arg1:T13 Arg2:T15	
R34	Used_for Arg1:T30 Arg2:T29	
R35	Causes Arg1:T29 Arg2:T14	
R36	Causes Arg1:T29 Arg2:T15	
R38	Experiences Arg1:T48 Arg2:T70	
R39	Has_Route_or_Mode Arg1:T16 Arg2:T51	
R42	Used_for Arg1:T30 Arg2:T71	
R43	Has_Route_or_Mode Arg1:T30 Arg2:T51	
#60	AnnotatorNotes T18	C1285356; Metabolic complication of procedures; Pathologic Function | C1393263; metabolic complications; Pathologic Function
R45	Causes Arg1:T31 Arg2:T18	
R46	Causes Arg1:T31 Arg2:T17	
R47	Has_Drug_Form Arg1:T19 Arg2:T52	
R49	Used_for Arg1:T19 Arg2:T73	
R51	Has_Route_or_Mode Arg1:T21 Arg2:T53	
R52	Has_Route_or_Mode Arg1:T19 Arg2:T53	
R53	Used_for Arg1:T19 Arg2:T31	
R54	Has_Age Arg1:T54 Arg2:T55	
T60	Observation 1028 1038	dispuestos
#61	AnnotatorNotes T60	C0600109; Willing; Finding
R55	Has_Quantifier_or_Qualifier Arg1:T57 Arg2:T60	
R56	Overlap Arg1:T60 Arg2:T25	
T74	Observation 1109 1116	capaces
#62	AnnotatorNotes T74	C1299581; Able (finding); Finding (?) | C1555472; Authorized; Finding (?)
R57	Has_Quantifier_or_Qualifier Arg1:T57 Arg2:T74	
R58	Overlap Arg1:T25 Arg2:T74	
R59	Experiences Arg1:T62 Arg2:T24	
R60	Experiences Arg1:T62 Arg2:T34	
R61	Negation Arg1:T63 Arg2:T24	
R62	Negation Arg1:T64 Arg2:T34	
R63	Has_Drug_Form Arg1:T26 Arg2:T66	
R64	Negation Arg1:T65 Arg2:T26	
R65	Causes Arg1:T26 Arg2:T24	
R66	Causes Arg1:T26 Arg2:T34	
R67	Experiences Arg1:T67 Arg2:T49	
R68	Experiences Arg1:T67 Arg2:T43	
R69	Experiences Arg1:T68 Arg2:T40	
R70	Used_for Arg1:T27 Arg2:T40	
#63	AnnotatorNotes T47	C1522726; Intravenous Route of Drug Administration; Functional Concept
R72	Has_Age Arg1:T56 Arg2:T55	
T75	Result_or_Value 1249 1269	entre 3 y 4.5 mmol/L
R73	Has_Result_or_Value Arg1:T32 Arg2:T75	
R74	Experiences Arg1:T59 Arg2:T32	
#64	AnnotatorNotes T32	C0202236; Triglycerides measurement; Laboratory Procedure
R75	Has_Duration_or_Interval Arg1:T39 Arg2:T61	
R76	Has_Duration_or_Interval Arg1:T23 Arg2:T61	
R77	Experiences Arg1:T59 Arg2:T39	
R78	Experiences Arg1:T59 Arg2:T23	
#65	AnnotatorNotes T42	C4520839; Emulsion (basic dose form); Biomedical or Dental Material
#66	AnnotatorNotes T46	C4520839; Emulsion (basic dose form); Biomedical or Dental Material
#67	AnnotatorNotes T52	C4520839; Emulsion (basic dose form); Biomedical or Dental Material
#68	AnnotatorNotes T66	C4520839; Emulsion (basic dose form); Biomedical or Dental Material
R6	Overlap Arg1:T31 Arg2:T21	
R8	Overlap Arg1:T29 Arg2:T16	
R13	Causes Arg1:T2 Arg2:T28	
R22	Causes Arg1:T8 Arg2:T12	
A8	Experiencer T54 Patient
A9	Experiencer T56 Patient
A10	Experiencer T57 Patient
A11	Experiencer T58 Other
A12	Experiencer T59 Patient
A13	Experiencer T62 Patient
A14	Experiencer T67 Patient
A15	Experiencer T68 Patient
A16	Experiencer T44 Patient
A17	Experiencer T48 Patient
